Christopher Ryan Sullivan Avalo Therapeutics, Inc. (AVTX) insider trading activity

AVTX Quotes by TradingView

Christopher Ryan Sullivan is Chief Financial Officer of Avalo Therapeutics, Inc.. Currently has a direct ownership of 16,921 shares of AVTX, which is worth approximately $143,151. The most recent transaction as insider was on Mar 28, 2025, when has been sold 7,285 shares (Common Stock) at a price of $8.46 per share, resulting in proceeds of $61,631. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 16.9K
1240.81% 3M change
1240.81% 12M change
Total Value Held $143,151

Christopher Ryan Sullivan Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 28 2025
SELL
Payment of exercise price or tax liability
$61,631 $8.46 p/Share
7,285 Reduced 30.1%
16,921 Common Stock
Mar 28 2025
BUY
Exercise of conversion of derivative security
-
24,200 Added 49.99%
24,206 Common Stock
Jun 09 2023
BUY
Open market or private purchase
$1,747 $3.42 p/Share
511 Added 28.82%
1,262 Common Stock
Dec 10 2021
BUY
Open market or private purchase
$1,499 $1.57 p/Share
955 Added 9.59%
9,004 Common Stock
Dec 10 2020
BUY
Open market or private purchase
$11,617 $2.28 p/Share
5,095 Added 38.76%
8,049 Common Stock
CRS

Christopher Ryan Sullivan

Chief Financial Officer
Rockville, MD

Track Institutional and Insider Activities on AVTX

Follow Avalo Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AVTX shares.

Notify only if

Insider Trading

Get notified when an Avalo Therapeutics, Inc. insider buys or sells AVTX shares.

Notify only if

News

Receive news related to Avalo Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on AVTX